- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
33
33 companies
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$518.66
7D
-0.3%
1Y
69.3%
Travere Therapeutics
Market Cap: US$4.1b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$44.91
7D
10.0%
1Y
109.8%
Zevra Therapeutics
Market Cap: US$595.3m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.05
7D
2.4%
1Y
25.6%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.96
7D
-5.0%
1Y
47.1%
Insmed
Market Cap: US$28.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$140.01
7D
3.0%
1Y
92.9%
AnaptysBio
Market Cap: US$1.9b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$69.78
7D
4.8%
1Y
236.6%
Ardelyx
Market Cap: US$1.7b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.30
7D
21.9%
1Y
95.4%
Rhythm Pharmaceuticals
Market Cap: US$5.6b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$85.58
7D
0.4%
1Y
32.9%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$33.50
7D
-4.6%
1Y
225.2%
Aldeyra Therapeutics
Market Cap: US$95.7m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.62
7D
2.5%
1Y
-40.0%
ARS Pharmaceuticals
Market Cap: US$850.0m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.83
7D
11.1%
1Y
-38.1%
Pelthos Therapeutics
Market Cap: US$83.9m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$24.82
7D
0.2%
1Y
108.6%
CG Oncology
Market Cap: US$5.8b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$67.70
7D
1.3%
1Y
140.2%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.49
7D
0.3%
1Y
52.4%
Belite Bio
Market Cap: US$6.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$154.51
7D
-5.2%
1Y
147.2%
SIGA Technologies
Market Cap: US$329.6m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.63
7D
1.5%
1Y
-14.3%
Verrica Pharmaceuticals
Market Cap: US$107.7m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.36
7D
-6.8%
1Y
42.7%
Neurocrine Biosciences
Market Cap: US$13.3b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$134.07
7D
4.7%
1Y
22.2%
Praxis Precision Medicines
Market Cap: US$9.0b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$337.61
7D
2.0%
1Y
766.6%
Citius Pharmaceuticals
Market Cap: US$19.0m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$0.71
7D
2.8%
1Y
-12.3%
BeOne Medicines
Market Cap: US$32.7b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$297.14
7D
-0.6%
1Y
16.9%
Fortress Biotech
Market Cap: US$75.0m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.38
7D
4.8%
1Y
33.7%
Journey Medical
Market Cap: US$141.8m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.12
7D
-2.7%
1Y
-25.5%
Gyre Therapeutics
Market Cap: US$712.2m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.92
7D
3.8%
1Y
-10.1%
Mirum Pharmaceuticals
Market Cap: US$5.9b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$105.79
7D
14.4%
1Y
139.6%
Fennec Pharmaceuticals
Market Cap: US$225.5m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.65
7D
-2.9%
1Y
5.9%
Benitec Biopharma
Market Cap: US$409.3m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.18
7D
-3.4%
1Y
-15.6%
Protagonist Therapeutics
Market Cap: US$6.3b
Operates as a discovery and development company in the United States.
PTGX
US$99.52
7D
1.0%
1Y
124.8%
Prothena
Market Cap: US$572.8m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.79
7D
0%
1Y
33.5%
Dyadic International
Market Cap: US$28.8m
A biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
DYAI
US$0.75
7D
-8.4%
1Y
-36.4%
Legend Biotech
Market Cap: US$4.4b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$26.50
7D
12.1%
1Y
-20.7%
Geron
Market Cap: US$1.0b
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.57
7D
2.6%
1Y
10.6%
Inovio Pharmaceuticals
Market Cap: US$90.1m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.14
7D
-2.6%
1Y
-38.7%